We thought, "Well, OK, we've got this drug, [Kadcyla], an antibody-drug conjugate, which in metastatic HER2-positive breast cancer had remarkable activity, particularly in patients whose cancer had ...

Kadcyla can extend the lives of women dying from an aggressive form of breast cancer. Campaigners claim more than a hundred women a year could benefit from the drug in Scotland.

Why do plant drugs kill cancer? We can agree that plants are largely oblivious to human suffering, so why do they make these compounds, is it just random chance? To answer that we need to think about ...

Kadcyla can cause life-threatening bleeding. Taking Kadcyla with other medications used to thin the blood (antiplatelet) or prevent blood clots (anticoagulation) can increase the risk of bleeding.

“ (Kadcyla) is the first therapy to show an improved survival after post-surgical therapy in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant therapy,” ...

“We are pleased that Kadcyla could offer people with HER2-positive early breast cancer with a particularly poor prognosis a chance to live longer and without recurrence of their disease,” said Levi ...

Pregnancy Receiving Kadcyla during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while receiving Kadcyla and for seven months after a patient’s ...

Roche <ROG.S> said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another win for the Swiss drugmaker in its second-biggest market where rising demand has helped ...

The European Commission has approved Roche’s Kadcyla (trastuzumab emtansine) for the adjuvant (after surgery) treatment of certain adult patients with HER2-positive early breast cancer. The approval ...

Metavivor Sue Wall-Cade has long been calling for better access to cancer drug Kadcyla. Now, Pharmac is planning to fund it. Photo / File It has been exhausting, frustrating and incredibly hard ...

In the meantime, AZ and Daiichi are hoping to take on Kadcyla in the second-line HER2 market as well as provide an additional third-line option in patients who progress despite treatment with Roche’s ...

And now, Kadcyla’s ready to run in a new indication. Monday, the FDA approved Kadcyla for adjuvant treatment of HER-2 positive, early breast cancer patients who didn’t fully respond to drug ...